Table 1.

Results obtained with MLC2 transgene

Transgene constructHeart/totalOther sitesFig.
5′ deletions
    5′Δ -299015/30 3A
    5′Δ -15587/12
    5′Δ -68120/51 3C
    5′Δ -24913/28 3D
    5′Δ -15910/50(8)3 BA, PN3E
    5′Δ -1275/27*(3)12 BA. PN 3F,G
    5′Δ -1110/8*6 BA, PN
    5′Δ -850/54*15 BA, S
Promoter fusions
    -1558/-48 (Cyt/tk)18/98 4A
    -249/-36 (Cyt)3/10 4B
    -1558/-249 (Cyt/tk)0/5*
    -681/-89 (Cyt)0/16*
    (-123/-41)2 (Cyt)5/5* 4C
    (-121/-81)2 (Cyt)0/12*3 BA 4D
    (-85/-42)2 (Cyt)0/10*3 spotty
Internal deletions
    Int.Δ -89/-493/45(1)7 various
    Int.Δ -89/-49 + 40bp3/7
Motif mutations
    PM-GATA#23/8 5A
    PM-GATA#2,33/10* 5B
    PM-GATA#1,20/12* 5C
    CArG-like mut0/11*
    YY1 mut2/6*(0)2 BA 6B
    CArG-like mut/YY1 mut3/25*(0)4 BA 6C
    CArG mut/YY1 mut12/15*(6)6 S, BA
  • Cyt/tk, cytoskeletal actin or tk minimal promoters; Int.Δ, internal deletion; PM, point mutations; BA, branchial arches; PN, pronephros; S, somites.

  • * Experiments performed with γ-crystallin GFP co-transgene. (Only embryos showing cotransgene expression were scored.)

  • When GFP expression was detected in other sites as well as the heart, values in parentheses indicate the number of embryos showing heart-only expression.

  • Promoter fragments tested with both Xenopus laevis cytoskeletal actin and herpes simplex thymidine kinase minimal promoters.